πŸ‡ΊπŸ‡Έ FDA

Intelligence Platform

Patents

Browse 763 pharma-relevant patents (US and EP, A61K/A61P) linked to tracked companies. Patent cliff and LOE intelligence for BD teams.

29,054 patents indexed
patent

US 12201655

Antimicrobial therapy

The Regents of the University of California Β· Granted Tue Jan 21 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jan 16 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12201658

Viral gene therapy as treatment for cholesterol storage disease or disorder

The United States of America, as represented by the Secretary, Department of Health and Human Services Β· Granted Tue Jan 21 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jan 16 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12201719

Combination therapy with semaphorin-4D blockade (SEMA4D) and DC1 therapy

VACCINEX, INC. Β· Granted Tue Jan 21 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jan 16 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12194016

Methods of providing solriamfetol therapy to subjects with impaired renal function

AXSOME MALTA LTD. Β· Granted Tue Jan 14 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jan 09 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12194061

Processes for production of tumor infiltrating lymphocytes and uses of same in immunothera

Iovance Biotherapeutics, Inc. Β· Granted Tue Jan 14 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jan 09 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12186428

Combination taxoid nanoemulsion with immunotherapy in cancer

Northwestern University Β· Granted Tue Jan 07 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jan 02 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12186369

Gene therapy strategy to restore electrical and cardiac function, and cardiac structure, i

The Regents of the University of California Β· Granted Tue Jan 07 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jan 02 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12178787

T cell receptors for immunotherapy

The Board of Regents of the University of Texas System Β· Granted Tue Dec 31 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Dec 26 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12173314

Gene therapy for recessive dystrophic epidermolysis bullosa using genetically corrected au

United States Government as represented by the Department of Veterans Affairs Β· Granted Tue Dec 24 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Dec 19 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12170134

Systems and methods for coordinating manufacturing of cells for patient-specific immunothe

Iovance Biotherapeutics, Inc. Β· Granted Tue Dec 17 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Dec 12 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12161733

Chemical conjugates of Evans Blue derivatives and their use as radiotherapy and imaging ag

The United States of America, as represented by the Secretary, Department of Health and Human Services Β· Granted Tue Dec 10 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Dec 05 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12156863

Combination cancer therapy with pentaaza macrocyclic ring complex and ascorbate compound

Galera Labs, LLC Β· Granted Tue Dec 03 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Nov 28 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12159700

Systems and methods for coordinating manufacturing of cells for patient-specific immunothe

Iovance Biotherapeutics, Inc. Β· Granted Tue Dec 03 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Nov 28 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12156879

Combining BACE1 inhibitors with mGluR agonists for Alzheimer's disease therapy

UNIVERSITY OF CONNECTICUT Β· Granted Tue Dec 03 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Nov 28 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12151001

Optimized expression cassettes for gene therapy

Tenaya Therapeutics, Inc. Β· Granted Tue Nov 26 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Nov 21 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12152242

CRISPR therapy

The Government of the United States of America as represented by the Secretary of the Deptartment of Health and Human Services Β· Granted Tue Nov 26 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Nov 21 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12121541

Processes for production of tumor infiltrating lymphocytes and uses of same in immunothera

Iovance Biotherapeutics, Inc. Β· Granted Tue Oct 22 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Oct 17 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12121580

Antibacterial photodynamic therapy using copper-cysteamine nanoparticles

The Board of Regents of the University of Texas System Β· Granted Tue Oct 22 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Oct 17 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12121540

CBL inhibitors and compositions for use in adoptive cell therapy

NURIX THERAPEUTICS, INC. Β· Granted Tue Oct 22 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Oct 17 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12115163

Combination therapy comprising a MAT2A inhibitor and a type II PRMT inhibitor

IDEAYA Biosciences, Inc. Β· Granted Tue Oct 15 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Oct 10 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12110334

Neutralizing antibodies to the Ξ±vΞ²8 integrin complex for immunotherapy

The Regents of the University of California Β· Granted Tue Oct 08 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Oct 03 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12110504

Gene therapy for recessive dystrophic epidermolysis bullosa using genetically corrected au

United States Government as represented by the Department of Veterans Affairs Β· Granted Tue Oct 08 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Oct 03 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12097213

Sequential treatment of cancers using 6-thio-dG, checkpoint inhibitors and radiation thera

The Board of Regents of the University of Texas System Β· Granted Tue Sep 24 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Sep 19 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12098385

Gene therapy strategy to restore cardiac electrical and structural function in arrhythmoge

The Regents of the University of California Β· Granted Tue Sep 24 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Sep 19 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted